Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv. , 2025, 15 , 231–243

RSC Advances, vol. 15, pp. 44437–44438

Abstract

This comment critically evaluates a study by Lu and colleagues, highlighting the misidentification and HeLa cell contamination in the three cell lines used to evaluate the anticancer properties of quinoline-based dihydrazone derivatives.

Authors 1

1. Ralf Weiskirchen corresponding Aachen Institute of Molecular Pathobiochemistry Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC)

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH Aachen University Hospital, Aachen, Germany